These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 6538092)

  • 1. Verapamil: a cause of sudden death in a patient with hypertrophic cardiomyopathy.
    Perrot B; Danchin N; Terrier de la Chaise A
    Br Heart J; 1984 Mar; 51(3):352-4. PubMed ID: 6538092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Arrhythmias in hypertrophic cardiomyopathy. Significance and therapeutic consequences].
    McKenna WJ; Kleinebenne A
    Herz; 1985 Apr; 10(2):91-101. PubMed ID: 2580767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of hypertrophic cardiomyopathy: relation to pathological mechanisms.
    Kaltenbach M; Hopf R
    J Mol Cell Cardiol; 1985 Jul; 17 Suppl 2():59-68. PubMed ID: 4040978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sudden death due to ventricular tachycardia during amiodarone therapy in familial hypertrophic cardiomyopathy.
    Gilligan DM; Missouris CG; Boyd MJ; Oakley CM
    Am J Cardiol; 1991 Oct; 68(9):971-3. PubMed ID: 1927963
    [No Abstract]   [Full Text] [Related]  

  • 5. Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy.
    Epstein SE; Rosing DR
    Circulation; 1981 Sep; 64(3):437-41. PubMed ID: 7196300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypertrophic cardiomyopathy: long-term effects of propranolol versus verapamil in preventing sudden death in "low-risk" patients.
    Pelliccia F; Cianfrocca C; Romeo F; Reale A
    Cardiovasc Drugs Ther; 1990 Dec; 4(6):1515-8. PubMed ID: 2081144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Echocardiographic and electrocardiographic evaluation of the effects of propranolol and verapamil in obstructive hypertrophic cardiomyopathy].
    Crittin J; Mayor C; Bloch A
    Ann Cardiol Angeiol (Paris); 1984 Apr; 33(3):185-9. PubMed ID: 6375537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Sudden death during Holter electrocardiographic monitoring in a patient with hypertrophic cardiomyopathy].
    Sato M; Takenaka K; Yamashita T; Koike S; Natori K; Nakahara K
    J Cardiol; 1998 May; 31(5):297-303. PubMed ID: 9617660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypertrophic cardiomyopathy. Combination of beta blockers and verapamil may be risky.
    Borja J; Izquierdo I; Guindo J
    BMJ; 2006 Jul; 333(7558):97. PubMed ID: 16825239
    [No Abstract]   [Full Text] [Related]  

  • 10. Adverse effects of atrial fibrillation and syncope induced by calcium-channel blockers in hypertrophic cardiomyopathy.
    Doiuchi J; Hamada M; Ochi T; Ito T; Kokubu T
    Clin Cardiol; 1985 Mar; 8(3):176-9. PubMed ID: 4038927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy.
    Gilligan DM; Chan WL; Joshi J; Clarke P; Fletcher A; Krikler S; Oakley CM
    J Am Coll Cardiol; 1993 Jun; 21(7):1672-9. PubMed ID: 8496536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effect of verapamil in hypertrophic cardiomyopathy.
    Hasin Y; Lewis BS; Lewis N; Weiss AT; Gotsman MS
    Int J Cardiol; 1982; 1(3-4):243-51. PubMed ID: 6807854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Syncope induced by propranolol in hypertrophic cardiomyopathy.
    García-Rubira JC; Pavón M; Romero-Chacón D
    Int J Cardiol; 1991 Jun; 31(3):358-61. PubMed ID: 1879988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complete Heart Block in Hypertrophic Cardiomyopathy: A Rare Association.
    Dubey L; Guruprasad S; Bhattacharya R; Subramanyam G
    Kathmandu Univ Med J (KUMJ); 2015; 13(52):372-4. PubMed ID: 27423292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regression of outflow tract obstruction subsequent to treatment with verapamil in hypertrophic obstructive cardiomyopathy.
    Frandsen F; Mickley H
    Int J Cardiol; 1990 Sep; 28(3):375-6. PubMed ID: 2210905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Verapamil-induced ventricular tachycardia in hypertrophic cardiomyopathy.
    Wessel A; Seiffert P; Dettmann R; Heintzen PH
    Eur Heart J; 1987 Mar; 8(3):313-5. PubMed ID: 3582389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypertrophic cardiomyopathy--therapy with slow channel inhibiting agents.
    Chatterjee K; Raff G; Anderson D; Parmley WW
    Prog Cardiovasc Dis; 1982; 25(3):193-210. PubMed ID: 6216500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Sudden death and obstructive hypertrophic cardiomyopathy].
    Baille N
    Ann Cardiol Angeiol (Paris); 1985 Mar; 34(3):155-60. PubMed ID: 3890678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ambulatory monitoring of aborted sudden cardiac death related to hypertrophic cardiomyopathy.
    Vaglio JC; Sorajja P; Gersh BJ
    Nat Clin Pract Cardiovasc Med; 2005 Dec; 2(12):659-62; quiz following 662. PubMed ID: 16306922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased serum lithium during verapamil therapy.
    Weinrauch LA; Belok S; D'Elia JA
    Am Heart J; 1984 Nov; 108(5):1378-80. PubMed ID: 6541864
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.